Maze Therapeutics, Inc.
MAZE
$25.56
-$0.87-3.29%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 58.61% | 39.67% | 13.14% | 41.82% | 27.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.50% | 28.03% | 23.33% | 43.34% | 26.37% |
| Operating Income | 24.99% | -28.03% | -36.06% | -126.14% | -26.37% |
| Income Before Tax | 26.16% | -15.79% | -20.20% | -123.92% | -0.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.16% | -16.87% | -21.55% | -124.22% | -0.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.16% | -16.87% | -21.55% | -124.22% | -0.90% |
| EBIT | 24.99% | -28.03% | -36.06% | -126.14% | -26.37% |
| EBITDA | 24.79% | -29.42% | -38.19% | -125.51% | -28.28% |
| EPS Basic | 60.78% | 67.91% | 93.59% | -105.06% | 21.44% |
| Normalized Basic EPS | 60.79% | 94.42% | 92.91% | -101.31% | 90.35% |
| EPS Diluted | 60.78% | 71.98% | 93.56% | -111.41% | 22.86% |
| Normalized Diluted EPS | 60.79% | 94.42% | 92.91% | -103.02% | 90.35% |
| Average Basic Shares Outstanding | 88.26% | 2,095.73% | 1,794.93% | 1,725.04% | 1,125.22% |
| Average Diluted Shares Outstanding | 88.26% | 2,095.73% | 1,794.93% | 693.47% | 1,125.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |